Alterity Therapeutics to Participate in the Benchmark Company Healthcare House Call Conference
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing diseas
Read More
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various forms of Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical to intercede in disease processes. Alterity is located in Melbourne, Australia and San Francisco, California, USA. The Company is listed on the Australian Securities Exchange (ASX: ATH) and NASDAQ (NASDAQ: ATHE).
Investment Highlights
- Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
- ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
- ATH434 has completed its Phase 1 clinical trial program.
- First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
- FDA Orphan Drug designation in the U.S. and EU for ATH434 for the treatment of MSA received.
- Significant market potential in MSA – estimated peak sales of US$725M.
Investor Resources
Corporate presentations
| March 8, 2022 | Corporate Presentation March 2022 | 5 MB |
ASX Announcements
2022
2021
2020
2019
2018
| February 10, 2019 | Appendix 3B – Cleansing Notice – Feb 2018 | 362 KB | |
| January 7, 2019 | Form 603 – Notice of Initial Substantial Holder Morgan Stanley – Jan 2018 | 543 KB | |
| January 7, 2019 | Form 603 – Notice of Initial Substantial Holder MUFG – Jan 2018 | 457 KB | |
| January 7, 2019 | Appendix 3B – Jan 2018 | 955 KB | |
| December 23, 2018 | PBT Trading Halt – Dec 2018 | 459 KB | |
| December 4, 2018 | Form S-8 Dec 2018 | 271 KB | |
| November 19, 2018 | Appendix 3B – Nov 2018 | 940 KB | |
| November 19, 2018 | Appendix 3Y Change of Director’s Interest Notice – Nov 2018 | 456 KB | |
| November 16, 2018 | Results of AGM 2018 | 186 KB | |
| November 16, 2018 | AGM Presentation – Nov 2018 | 621 KB | |
| October 16, 2018 | Notice of AGM – Oct 2018 | 849 KB | |
| July 16, 2018 | Appendix 3B and 708A Notice – Jul 2018 | 248 KB | |
| June 27, 2018 | Investor Presentation – Jun 2018 | 5 MB | |
| January 22, 2018 | Appendix 3B – Jan 2018 | 809 KB |
Financial reports
2022
| April 29, 2022 | Appendix 4C and Q3 FY 222 Quarterly Cash Flow Report – 29 April 2022 | 1 MB | |
| January 27, 2022 | Appendix 4C – Q2 FY22 Quarterly Cash Flow Report – 27 January 2022 | 422 KB |
2021
| October 29, 2021 | Appendix 4C – September 2021 | 2 MB | |
| September 3, 2021 | Form 20-F 2021 | 776 KB | |
| September 1, 2021 | Annual Report 2021 | 3 MB | |
| July 30, 2021 | Appendix 4C-June 2021 | 411 KB | |
| April 29, 2021 | Appendix 4C – March 2021 | 418 KB | |
| February 25, 2021 | Appendix 4D 2020 | 374 KB |
2020
| January 29, 2021 | Appendix 4C- December 2020 | 339 KB | |
| October 30, 2020 | Appendix 4C- September 2020 | 354 KB | |
| September 16, 2020 | Form 20-F 2020 | 2 MB | |
| September 9, 2020 | Appendix 4G Ended 30 June 2020 | 374 KB | |
| September 9, 2020 | Annual Report 2020 | 2 MB | |
| August 31, 2020 | Appendix 4E Year ended 30 June 2020 | 454 KB | |
| July 30, 2020 | Appendix 4C – June 2020 | 384 KB | |
| April 30, 2020 | Appendix 4C – March 2020 | 346 KB | |
| February 28, 2020 | Form 6-K Feb 2020 | 233 KB | |
| February 28, 2020 | Appendix 4D 2019 | 410 KB | |
| January 31, 2020 | Appendix 4C – December 2019 | 372 KB |
2019
| October 30, 2019 | Appendix 4C – September 2019 | 346 KB | |
| September 2, 2019 | Form 20-F 2019 | 828 KB | |
| August 30, 2019 | Appendix 4G FY Ended 2019_06_30 | 341 KB | |
| August 30, 2019 | Annual Report 2019 | 1 MB | |
| August 1, 2019 | Appendix 4C – June 2019 | 151 KB | |
| May 13, 2019 | Form-6-K-2019_03_01 | 400 KB | |
| April 16, 2019 | Appendix 4C – Mar 2019 | 161 KB | |
| February 28, 2019 | Form 6-K – Mar 2019 | 400 KB | |
| February 28, 2019 | Appendix 4D 2018 | 217 KB | |
| January 31, 2019 | Appendix 4C – Dec 2018 | 234 KB |
2018
| May 13, 2019 | Form 6-K Feb 2018 | 148 KB | |
| October 30, 2018 | Appendix 4C – Sept 2018 | 170 KB | |
| September 3, 2018 | Form 20F – 2018 | 2 MB | |
| August 31, 2018 | Appendix 4G FY Ended 2018_06_30 | 123 KB | |
| August 31, 2018 | Annual Report 2018 | 2 MB | |
| July 30, 2018 | Appendix 4C – Jun 2018 | 262 KB | |
| May 7, 2018 | Appendix 4C – Mar 2018 | 263 KB | |
| March 4, 2018 | Form 6-K Feb 2018 | 148 KB |
Corporate governance
| September 1, 2021 | Corporate Governance Statement 2021 | 134 KB | |
| November 18, 2020 | ATH – Constitution (Amended) | 433 KB | |
| April 29, 2020 | Board Charter | 1 MB | |
| May 15, 2019 | Whistle Blower Policy | 320 KB | |
| May 15, 2019 | Securities Trading Policy | 343 KB | |
| May 15, 2019 | Diversity Policy | 197 KB | |
| November 23, 2020 | 2018 ADS Plan (as amended) | 100 KB | |
| November 23, 2020 | 2004 ASX Plan (as amended) | 52 KB |
News
Appendix 4C – Q3 FY22 Quarterly Cash Flow Report
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developin
Read MoreAlterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that the United Kingdom Medicines &
Read More
Appendix 4C – Q1 FY22 Quarterly Cash Flow Report
Highlights: New details on ATH34 Phase 2 clinical trial released. Data from bioMUSE presented at International Parkinson and Movement Disord
Read MoreReceive news from Alterity Therapeutics
